FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999233789> ?p ?o ?g. }

• W2999233789 endingPage "1014" @default.
• W2999233789 startingPage "1000" @default.
• W2999233789 abstract "To address the problem of poor asthma control due to drug resistance, an antisense oligonucleotide complementary to mmu-miR-145a-5p (antimiR-145) was tested in a house dust mite mouse model of mild/moderate asthma. miR-145 was targeted to reduce inflammation, regulate epithelial-mesenchymal transitions, and promote differentiation of structural cells. In addition, several chemical variations of a nontargeting oligonucleotide were tested to define sequence-dependent effects of the miRNA antagonist. After intravenous administration, oligonucleotides complexed with a pegylated cationic lipid nanoparticle distributed to most cells in the lung parenchyma but were not present in smooth muscle or the mucosal epithelium of the upper airways. Treatment with antimiR-145 and a nontargeting oligonucleotide both reduced eosinophilia, reduced obstructive airway remodeling, reduced mucosal metaplasia, and reduced CD68 immunoreactivity. Poly(A) RNA-seq verified that antimiR-145 increased levels of many miR-145 target transcripts. Genes upregulated in human asthma and the mouse model of asthma were downregulated by oligonucleotide treatments. However, both oligonucleotides significantly upregulated many genes of interferon signaling pathways. These results establish effective lung delivery and efficacy of locked nucleic acid/DNA oligonucleotides administered intravenously, and suggest that some of the beneficial effects of oligonucleotide therapy of lung inflammation may be due to normalization of interferon response pathways. To address the problem of poor asthma control due to drug resistance, an antisense oligonucleotide complementary to mmu-miR-145a-5p (antimiR-145) was tested in a house dust mite mouse model of mild/moderate asthma. miR-145 was targeted to reduce inflammation, regulate epithelial-mesenchymal transitions, and promote differentiation of structural cells. In addition, several chemical variations of a nontargeting oligonucleotide were tested to define sequence-dependent effects of the miRNA antagonist. After intravenous administration, oligonucleotides complexed with a pegylated cationic lipid nanoparticle distributed to most cells in the lung parenchyma but were not present in smooth muscle or the mucosal epithelium of the upper airways. Treatment with antimiR-145 and a nontargeting oligonucleotide both reduced eosinophilia, reduced obstructive airway remodeling, reduced mucosal metaplasia, and reduced CD68 immunoreactivity. Poly(A) RNA-seq verified that antimiR-145 increased levels of many miR-145 target transcripts. Genes upregulated in human asthma and the mouse model of asthma were downregulated by oligonucleotide treatments. However, both oligonucleotides significantly upregulated many genes of interferon signaling pathways. These results establish effective lung delivery and efficacy of locked nucleic acid/DNA oligonucleotides administered intravenously, and suggest that some of the beneficial effects of oligonucleotide therapy of lung inflammation may be due to normalization of interferon response pathways." @default.
• W2999233789 created "2020-01-23" @default.
• W2999233789 creator A5014947126 @default.
• W2999233789 creator A5017148065 @default.
• W2999233789 creator A5019245550 @default.
• W2999233789 creator A5027326839 @default.
• W2999233789 creator A5029447355 @default.
• W2999233789 creator A5038259200 @default.
• W2999233789 creator A5039552337 @default.
• W2999233789 creator A5045713586 @default.
• W2999233789 creator A5057273511 @default.
• W2999233789 creator A5086100040 @default.
• W2999233789 date "2020-03-01" @default.
• W2999233789 modified "2023-10-15" @default.
• W2999233789 title "Nanoparticle Delivery of Anti-inflammatory LNA Oligonucleotides Prevents Airway Inflammation in a HDM Model of Asthma" @default.
• W2999233789 cites W1046554971 @default.
• W2999233789 cites W1721251433 @default.
• W2999233789 cites W1847766730 @default.
• W2999233789 cites W1935952500 @default.
• W2999233789 cites W1970837893 @default.
• W2999233789 cites W1980818895 @default.
• W2999233789 cites W1982781008 @default.
• W2999233789 cites W1985182966 @default.
• W2999233789 cites W1988623729 @default.
• W2999233789 cites W1989601387 @default.
• W2999233789 cites W1995409627 @default.
• W2999233789 cites W1996630410 @default.
• W2999233789 cites W1999716006 @default.
• W2999233789 cites W2004295257 @default.
• W2999233789 cites W2007736853 @default.
• W2999233789 cites W2021701428 @default.
• W2999233789 cites W2023304501 @default.
• W2999233789 cites W2032617145 @default.
• W2999233789 cites W2032913523 @default.
• W2999233789 cites W2035908500 @default.
• W2999233789 cites W2054316761 @default.
• W2999233789 cites W2055515566 @default.
• W2999233789 cites W2056743382 @default.
• W2999233789 cites W2057930810 @default.
• W2999233789 cites W2058225109 @default.
• W2999233789 cites W2061435251 @default.
• W2999233789 cites W2070287533 @default.
• W2999233789 cites W2072196657 @default.
• W2999233789 cites W2074641102 @default.
• W2999233789 cites W2082893668 @default.
• W2999233789 cites W2095474857 @default.
• W2999233789 cites W2098664489 @default.
• W2999233789 cites W2100037149 @default.
• W2999233789 cites W2107534203 @default.
• W2999233789 cites W2111065008 @default.
• W2999233789 cites W2111783800 @default.
• W2999233789 cites W2112433605 @default.
• W2999233789 cites W2113562144 @default.
• W2999233789 cites W2114557056 @default.
• W2999233789 cites W2116895538 @default.
• W2999233789 cites W2117409112 @default.
• W2999233789 cites W2119030912 @default.
• W2999233789 cites W2119346726 @default.
• W2999233789 cites W2130410032 @default.
• W2999233789 cites W2131271579 @default.
• W2999233789 cites W2135536194 @default.
• W2999233789 cites W2137517624 @default.
• W2999233789 cites W2138207763 @default.
• W2999233789 cites W2148502571 @default.
• W2999233789 cites W2154435261 @default.
• W2999233789 cites W2156415904 @default.
• W2999233789 cites W2162886201 @default.
• W2999233789 cites W2164092307 @default.
• W2999233789 cites W2166997969 @default.
• W2999233789 cites W2179438025 @default.
• W2999233789 cites W2214074259 @default.
• W2999233789 cites W2316489974 @default.
• W2999233789 cites W2328404261 @default.
• W2999233789 cites W2329713786 @default.
• W2999233789 cites W2337074695 @default.
• W2999233789 cites W239448157 @default.
• W2999233789 cites W2410597558 @default.
• W2999233789 cites W2561612116 @default.
• W2999233789 cites W2571895431 @default.
• W2999233789 cites W2726386605 @default.
• W2999233789 cites W2754663824 @default.
• W2999233789 cites W2807776209 @default.
• W2999233789 cites W2888547609 @default.
• W2999233789 cites W2892016825 @default.
• W2999233789 cites W2898861582 @default.
• W2999233789 cites W2917207851 @default.
• W2999233789 cites W4232534952 @default.
• W2999233789 doi "https://doi.org/10.1016/j.omtn.2019.12.033" @default.
• W2999233789 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7013130" @default.
• W2999233789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32044723" @default.
• W2999233789 hasPublicationYear "2020" @default.
• W2999233789 type Work @default.
• W2999233789 sameAs 2999233789 @default.
• W2999233789 citedByCount "18" @default.
• W2999233789 countsByYear W29992337892020 @default.
• W2999233789 countsByYear W29992337892021 @default.
• W2999233789 countsByYear W29992337892022 @default.
• W2999233789 countsByYear W29992337892023 @default.

• next